Lymphoma

Lymphoma

As part of Taussig Cancer Institute's mission to improve patient outcomes, lymphoma program staff constantly update and review standard-of-care treatments, participate in clinical trials of new treatment strategies, and work closely with the blood and marrow transplant program. The results of this carefully coordinated approach are reflected in the outcomes shown in the survival curves included here.

Five-Year Overall Survival of Patients With Aggressive Non-Hodgkin Lymphoma by Disease Type (N = 1272)

2009-2019

Number at RiskYear 1Year 2Year 3Year 4Year 5
Burkitt Lymphoma (N = 56)4033292310
DLBCL (N = 1059)821619461349219
Mantle Cell (N = 157)141108886040

DLBCL = diffuse large B-cell lymphoma

Five-Year Overall Survival of Patients With Indolent Non-Hodgkin Lymphomaᵃ (Follicular Lymphoma vs. Other Indolent Subtypes) (N = 1108)

2009-2019

Number at RiskYear 1Year 2Year 3Year 4Year 5
Follicular (N = 553)516420341262171
Nonfollicular (N = 555)517425333259159

ᵃIncludes Waldenstoms macroglobulinemia, lymphoplasmacytic, marginal b-cell, splenic marginal b cell, cutaneous t-cell

Five-Year Overall Survival of Patients With Hodgkin Lymphoma (N = 407)

2009-2019

Five-Year Overall Survival of Patients With Chronic Lymphocytic Leukemiaᵃ (N = 510)

2009-2019

ᵃB-cell chronic lymphocytic leukemia/small lymphocytic lymphoma